Streetbeat News

Products Services

NTDOY

Nintendo Company Ltd. (OTC:NTDOY) has announced the termination of its Nintendo Switch repair subscription service in Japan after only one year of operation. The service, which allowed subscribers to access up to six repairs annually, will cease accepting new contracts and renewals from August 31, 2023. Existing customers can continue to use the service until their contracts expire. The decision comes amid persistent issues with the Nintendo Switch's Joy-Con controllers, which have led to numerous lawsuits against the company.

Portfolio Pulse from Franca Quarneti

July 05, 2023 | 9:28 pm

ATOMUSD

ETHUSD

Decentralized exchange dYdX is migrating from its Ethereum-based platform to Cosmos, with a public testnet now launched. The testnet will initially feature Bitcoin and Ethereum markets, with plans to expand to over 30 markets. The existing Ethereum-based platform has recorded over $728 million in trading volume in the last 24 hours. The platform's governance token, DYDX, has risen by 23% over the past two weeks. The main network on Cosmos is expected to launch later this year.

Portfolio Pulse from Murtuza Merchant

July 05, 2023 | 9:21 pm

META

Jim Cramer, a CNBC host, has expressed his support for Meta Platforms Inc's (NASDAQ:META) upcoming social media platform, Threads, over Twitter. Cramer believes that dissatisfaction among Twitter's 300 million users presents an opportunity for Threads. His comments come after Twitter, under Elon Musk's leadership, faced backlash for limiting the number of posts users can see per day and for introducing a subscription feature called Twitter Blue.

Portfolio Pulse from Adam Eckert

July 05, 2023 | 9:19 pm

PMBHF

PharmAla Biotech Holdings Inc.'s (OTC:PMBHF) Australian joint venture Cortexa has placed its first order for PharmAla’s GMP-compliant MDMA. The order, worth approximately $300,000, will be shipped on an expedited basis. The company is also planning to order GMP-compliant psilocybin API. This comes as Australia's psychedelic program launches, with regulatory changes allowing for the use of MDMA and psilocybin by authorized prescribers from July 1.

Portfolio Pulse from Lara Goldstein

July 05, 2023 | 8:55 pm

AMZN

RIVN

Rivian is reportedly in final negotiations with Amazon to sell its electric vans to other customers. This move could potentially expand Rivian's customer base and increase its revenues.

Portfolio Pulse from Charles Gross

July 05, 2023 | 8:47 pm

DMTTF

Small Pharma Inc. (OTCQB:DMTTF) has announced a cost-cutting strategy, changes in its management team, and an update to its R&D strategy. The company aims to expedite the clinical program of its novel deuterated DMT compound SPL028, which is currently in Phase 1 study. Preliminary findings show that SPL028 produces a psychedelic experience of less than one hour and is well-tolerated. The company's co-founder, Peter Rands, has left his positions, and the company is also reducing its headcount by 30%. Topline data from the ongoing Phase 1 study is expected in Q4 2023.

Portfolio Pulse from Lara Goldstein

July 05, 2023 | 8:46 pm

ASLN

ASLAN Pharmaceuticals will host a webcast on July 6, 2023, to discuss Phase 2b topline data from the TREK-AD trial evaluating Eblasakimab in Atopic Dermatitis.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2023 | 8:31 pm

AMZN

ROKT

UFO

Blue Origin, the aerospace manufacturer founded by Amazon's Executive Chairman Jeff Bezos, is planning to establish international launch sites as part of its global expansion strategy. This move follows the company's domestic progress, including partnerships with NASA and successful launches. The expansion could impact related companies like Amazon and SpaceX, as well as ETFs like the Procure Space ETF (NYSE:UFO) and the SPDR S&P Kensho Final Frontiers ETF (NYSE:ROKT).

Portfolio Pulse from Benzinga Newsbot

July 05, 2023 | 8:18 pm

VSTM

Verastem Oncology has finalized the design of its Phase 3 trial for the combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer. The trial, RAMP 301, will commence in the second half of 2023. The company also intends to file for accelerated FDA approval based on data from RAMP 201 and the FRAME trial. As of March 31, 2023, Verastem had cash and short-term investments of $111.2M, which increased to approximately $202.7M after a public offering in June 2023.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 8:11 pm

CBUS

Cibus, Inc. (NASDAQ:CBUS), an agricultural technology company, has welcomed the European Commission's proposal on the regulation of plants obtained from New Genomic Techniques (NGTs). The proposal aims to adapt EU legislation to scientific and technological progress, enabling NGTs to contribute to sustainable agriculture, climate resilience, and food security. The proposed regulation identifies a 'Conventional-like' category of NGT products that would be regulated as conventional varieties. Products from Cibus' gene editing platform, such as canola and oilseed rape resistant to disease or with reduced seed losses, would be considered 'Conventional-like'.

Portfolio Pulse from Happy Mohamed

July 05, 2023 | 8:10 pm